Docetaxel Toxicity Optimization in Esophageal Squamous Cell Carcinoma Cell Line YM-1: A Study of Cell Cycle and Doubling Time Effect

Abstract

Background and objectives: Docetaxel is a chemotherapeutic agent commonly used for treatment of many cancers, including esophageal squamous cell carcinoma. Docetaxel induces G2/M phase cell cycle arrest and ultimately cell death. In this study, we aimed to assess the effects of docetaxel on YM1 cells considering exposure time and dose.Methods: After calculating the doubling time of YM1 cells, the anti-proliferative effect of different concentrations of docetaxel (0.1-10 nM) after 24, 48 and 72 hours was assessed by the standard colorimetric assay. In addition, the effect of docetaxel on cell cycle was evaluated by flow cytometry.Results: The results showed that docetaxel toxicity was not significant until 24 hours at the tested concentrations (P>0.05). In addition, the effect of docetaxel on the cells was time-dependent at all tested concentrations. Overall, the duration of exposure to docetaxel had more significant role in docetaxel toxicity in YM1 cells compared to concentration. Conclusion:Our findings suggest that the cytotoxicity of docetaxel on YM1 cells is time-dependent.

Review; Recent approaches on Tubulin Polymerization inhibitors (2018-2022)

“…They have attracted medicinal chemists attention in the past two decades. Several natural compounds such as paclitaxel (Mosca, Ilari, Fazi, Assaraf, & Colotti, 2021), docetaxel (Khosravi & Asadi, 2021), vincristine (Škubník, Pavlíčková, Ruml, & Rimpelová, 2021), vinblastine (Chagas & Alisaraie, 2019), combretastatin (CA-4) (Siemann, Chaplin, & Walicke, 2009), colchicine (Lin, Kuo, Wu, & Chuang, 2016), podophyllotoxin (Shah et al, 2021) and resveratrol(L. act by altering microtubule dynamics (figure 2). These drugs have significantly improved survival rates and management of several cancer types among children and adults.…”